Actively Recruiting
PET Image Exploration of Novel Tracer 68Ga-FAPI-JNU in Patients with Malignant Tumors
Led by Affiliated Hospital of Jiangnan University · Updated on 2025-01-22
30
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating the distribution of a new tracer called 68Ga-FAPI-JNU in patients with malignant tumors, including primary tumors, metastases, and normal tissues. The study aims to evaluate how this tracer spreads in the body using standardized uptake values to better understand its behavior in cancer imaging. Participants receive an injection of approximately 2-5 mCi of the novel tracer 68Ga-FAPI-JNU through a vein on the back of the hand. About one hour after injection, a PET/CT scan is performed to capture images of the tracer's distribution. Two experienced diagnostic physicians analyze the scans to map maximum and mean standardized uptake values in areas of interest. During the study, participants will undergo the tracer injection and PET/CT imaging as described. The main measurement is the evaluation of tracer distribution in tumors, metastases, and normal tissues within four hours. The study involves assessments by imaging specialists and adheres to protocol requirements to ensure accurate data collection. Total participation duration varies based on individual scheduling.
CONDITIONS
Brief Title
PET Image Exploration of Novel Tracer [68Ga]-FAPI-JNU Imaging Studies in Patients with Malignant Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants voluntarily sign informed consent and can complete the test according to protocol
- Age between 18 and 85 years, male or female
- Clinically diagnosed malignant tumor confirmed by biopsy or imaging such as CT or MRI
- ECOG performance status score between 0 and 3
You will not qualify if you...
- History of allergy or allergic constitution to any component of the tracer, including alcohol
- Pregnant or lactating women
- Patients with mental illness or related history
- Patients unable to undergo a PET/CT scan
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 1 day
Participants receive an injection of the novel tracer 68Ga-FAPI-JNU followed by a PET/CT scan approximately 1 hour later to evaluate tracer distribution in tumors and tissues.
1 visit (in-person)
Trial Site Locations
Total: 1 location
1
Affiated Hospital of Jiangnan University
Wuxi, Jiangsu, China, 214000
Actively Recruiting
Research Team
C
chunjing Yu
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here